PMID

Data

Article Title

Organization

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Sloan-Kettering Institute For Cancer Research

Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.

Vertex Pharmaceuticals

Correlation between chemotype-dependent binding conformations of HSP90a/ß and isoform selectivity-Implications for the structure-based design of HSP90a/ß selective inhibitors for treating neurodegenerative diseases.

Vertex Pharmaceuticals

Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.

Memorial Sloan-Kettering Cancer Center

EC144 is a potent inhibitor of the heat shock protein 90.

Biogen Idec

Heat shock protein 90: inhibitors in clinical trials.

Biogen Idec

New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting.

University Of Ferrara

Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.

Ulsan National Institutes Of Science And Technology (Unist)